The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Sep. 28, 6:08 PM

Slide #23. Sarepta Therapeutics, Inc. Secondary Offering

Company: Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Date announced: 9/21/2016
Shares Offered: 5,020,000
Date of Pricing: 9/22/2016
Price Per Share: $59.75
Secondary Offering Details: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering. -updated 9/22- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock at a price to the public of $59.75 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 753,138 shares of common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $300 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 28, 2016, subject to customary closing conditions.

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. Co. targets a range of diseases and disorders through distinct RNA-targeted mechanisms of action. Co. is primarily focused on the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates, including its main DMD product candidate, eteplirsen, designed to skip exon 51. Co. is also developing therapeutics using its technology for the treatment of drug resistant bacteria and infectious, rare and other human diseases.

SRPT SEC Filing Email Alerts Service

Open the SRPT Page at The Online Investor »

Company Name:  Sarepta Therapeutics Inc
Sector:  Biotechnology
Number of ETFs Holding SRPT:  18
Total Market Value Held by ETFs:  $230.82M
Total Market Capitalization:  $2.77B
% of Market Cap. Held by ETFs:  8.33%

Open the SRPT Page at The Online Investor (in a new window) »

September 28, 2016    6:08 PM Eastern
Quotes delayed 20 minutes

Buy (3.38 out of 4)
66th percentile
(ranked higher than approx. 66% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.